Usage Examples
- The indication was granted under Accelerated Approval on response rate, so the confirmatory study is a condition of keeping it.
- Route the launch deck through regulatory first: this is an Accelerated Approval product and promotional material goes to FDA before dissemination.
- If the confirmatory study slips again, our Accelerated Approval is exposed on due diligence, not only on the readout.
What is Accelerated Approval (AA)?
Accelerated Approval is an FDA pathway that grants marketing approval for serious or life-threatening illnesses on a surrogate endpoint reasonably likely to predict clinical benefit, conditioned on postmarketing studies that verify and describe that benefit.
Accelerated Approval exists because, for serious or life-threatening illnesses, waiting on survival or irreversible-morbidity data can add years to a program while patients have no adequate therapy. Accelerated Approval moves the approval decision onto an earlier signal, a surrogate endpoint reasonably likely to predict clinical benefit, and shifts the burden of proving real benefit into the postmarketing period.
Accelerated Approval covers new drugs under 21 CFR part 314, subpart H and biological products under 21 CFR part 601, subpart E, on the same standard. Accelerated Approval does not lower the safety and effectiveness bar, shorten FDA's review clock, or make the confirmatory study optional. It changes the endpoint approval rests on, and nothing else.
Accelerated Approval is applied in practice through two gates: the confirmatory study and promotional material review. The study should usually already be underway at approval, must be adequate and well-controlled, and must be carried out with due diligence. Accelerated Approval also requires launch promotional materials to reach FDA during the preapproval review period, then 30 days ahead of use afterward.
Not to be confused with
- Priority Review
- Priority Review compresses the agency's review timeline for an application. Accelerated Approval changes the evidence the approval can rest on. A product can carry one, both, or neither.
- Breakthrough Therapy
- a development-stage designation that intensifies FDA interaction during the program. It does not by itself permit approval on a surrogate endpoint; that authority comes from subpart H or subpart E.
- Approval with restrictions (21 CFR 314.520)
- a separate provision in the same subpart, keyed to restricted distribution or use rather than to the endpoint. The withdrawal procedures in 21 CFR 314.530 reach both.
- Postmarketing commitment
- a confirmatory study under Accelerated Approval is a condition of the approval whose failure or slow conduct is an express withdrawal ground, not a voluntary undertaking negotiated at the margin.
The obligations run from approval through launch promotion and stay live for as long as the approval does.
What you must do
- 1Establish, in adequate and well-controlled clinical trials, an effect on a surrogate endpoint reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit21 CFR 314.510
- 2Conduct the required postmarketing studies to verify and describe clinical benefit where uncertainty exists about the surrogate's relation to benefit, keep them adequate and well-controlled, and carry them out with due diligence21 CFR 601.41
- 3Submit to FDA, during the preapproval review period, copies of all promotional materials intended for dissemination or publication within 120 days following marketing approval21 CFR 314.550
- 4After that first 120 days, submit promotional materials at least 30 days before initial dissemination of the labeling or initial publication of the advertisement21 CFR 314.550
- 5Hold the conditions that keep the approval intact, including verified benefit, diligent study conduct, adherence to agreed postmarketing restrictions, and promotion that is not false or misleading, since each is an independent withdrawal ground21 CFR 314.530
Common mistakes
Starting the confirmatory study after approval
the regulation contemplates postmarketing studies that are usually already underway. A study that is still being designed at approval reads as a due-diligence problem, and failure to perform the required study with due diligence is its own ground for withdrawal, separate from the result.
Running launch promotion on the ordinary advertising timeline
subpart H pulls promotional material review forward into the preapproval period for everything intended for the first 120 days, then holds a 30-day pre-use window after that. Commercial teams that plan to the normal cadence miss the window, and false or misleading promotion is itself a withdrawal ground.
Treating Accelerated Approval as a speed lever on review
it alters the endpoint the approval rests on, not the review clock. Programs that build timelines around it as a review accelerator plan against the wrong variable and under-resource the confirmatory study that actually determines whether the indication survives.
When This Matters
- The indication was granted under Accelerated Approval on response rate, so the confirmatory study is a condition of keeping it.
- Route the launch deck through regulatory first: this is an Accelerated Approval product and promotional material goes to FDA before dissemination.
- If the confirmatory study slips again, our Accelerated Approval is exposed on due diligence, not only on the readout.
Frequently Asked Questions
A surrogate endpoint is a marker that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit, without being a direct measure of survival or irreversible morbidity. FDA can approve a drug on that evidence, but the applicant must then run postmarketing studies that verify and describe the actual clinical benefit.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
